Blood Neoplasia
Издатель: Elsevier · ISSN 2950-3280 · 90 статей
- Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models
- The KDM-family inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing a ferroptosis-like phenotype
- CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?
- Real-world pharmacokinetics of venetoclax in patients with acute myeloid leukemia in Japan
- Post-transplant outcomes after intensive chemotherapy versus hypomethylating agent/venetoclax in acute myeloid leukemia
- Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study
- Hypomethylating agents–venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT
- Self-supervised learning can distinguish myelodysplastic neoplasms from clinical mimics using bone marrow biopsies
- Expression of RUNX1::RUNX1T1 deregulates the proteome, induces C/EBPβ suppression, and blocks myeloid differentiation
- Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS
- ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma
- Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent IDH1 mutation
- Deletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia
- Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia
- Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden
- Liquid biopsy for molecular profiling in cutaneous T-cell lymphoma: a pilot feasibility study
- Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial
- Epigenetics as a mechanism of lineage extinction and relapse of B-cell lymphoma treated with CD19 CAR T-cell therapy
- Ten-day decitabine vs “3+7” in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21
- Clinical features and outcomes of MPN with concurrent MPL and JAK2/CALR Mutations
- Somatic UBA1 mutations in pediatric MDS/AML: first cases suggest distinct pathogenesis from adult VEXAS syndrome
- Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera
- Evaluating response criteria in myelodysplastic/myeloproliferative neoplasms: a systematic review and meta-analysis
- FLT3 (CD135) expression in pediatric AML is associated with distinct features and worse outcomes with sorafenib therapy
- Multilayer modeling reveals an endogenous retrovirus signature predictive of induction chemotherapy failure in AML
- Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036.
- EZH2-driven immune evasion at disease presentation defines high-risk t(16;21) FUS::ERG pediatric AML
- Long-read cDNA sequencing reveals novel isoforms and spliceosome mutant-enriched transcripts in AML and MDS cells
- Dasatinib-based induction and blinatumomab + TKI consolidation/maintenance for BCR::ABL1+ ALL: BLISSPhALL Study Results
- Trends in Survival of Marginal Zone Lymphoma by Treatment Era in the United States